First Research Paper
Dr. Guy Weinberg publishes research paper on lipid emulsion correcting cardiotoxicity caused by LAST in an animal model.
First Human Case
First case of lipid emulsion being used to treat LAST in a human. Recalling Dr. Weinberg’s paper, Dr. Meg Rosenblatt administers intravenous lipid emulsion (ILE) to a patient who had gone into cardiac arrest after being administered Bupivacaine for shoulder surgery.
ResQ Pharma, LLC
Formation of ResQ Pharma, LLC.
First Non-Opioid Drug Overdose Registry
The first registry study involving the use of lipid emulsion for non-opioid drug overdose was published with data collected from 2008-2009 on a retrospective basis.
Correspondence with FDA
First correspondence with FDA seeking approval of a lipid emulsion product for the treatment of LAST.
ResQ Hires CEO
ResQ hires Paul Burton as Chief Executive Officer.
ResQ Pharma, Inc.
ResQ Pharma, LLC converts to ResQ Pharma, Inc.
First Seed Round
ResQ completes first seed round financing at $325,000.
ResQ Pharma, Inc. acquires patents from the University of Illinois at Chicago.
Second Seed Round
ResQ completes the second seed round financing at $739,359.
The FDA provides written guidance for ResQ Pharma to file a literature based NDA for the LAST indication.
Orphan Drug Designation
The FDA grants ResQ Pharma’s orphan drug designation request for the treatment of LAST.
ResQ enters into a manufacturing agreement with CordenPharma Caponago.
© 2018 ResQ Pharma, Inc.